pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.33k
4.33k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
11361Y | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13293P | adalimumab | Humira | Injection 20 mg in 0.2 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,332 | 2,024 | SEPTEMBER |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
8778B | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12013G | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12013G | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
9099X | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13209F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
13209F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
10073E | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10073E | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10073E | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10073E | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10073E | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10073E | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
3445H | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
3445H | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
3445H | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
3445H | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
10905Y | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
10905Y | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
10905Y | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13705H | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | Subsequent continuing treatment | 14555 | true | STREAMLINED | Private | 4,332 | 2,024 | SEPTEMBER |
12401Q | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12401Q | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12401Q | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12401Q | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12401Q | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
13339C | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14164 | true | STREAMLINED | Public | 4,332 | 2,024 | SEPTEMBER |
13226D | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
13226D | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
13226D | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
13226D | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
14286X | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,332 | 2,024 | SEPTEMBER |
11721X | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | giant cell arteritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12365T | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12365T | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12365T | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12365T | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12365T | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
10079L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,332 | 2,024 | SEPTEMBER |
12415K | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12415K | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12415K | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12415K | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12415K | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
13744J | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
11202N | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Subsequent continuing treatment | 9156 | true | STREAMLINED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
12361N | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
11219L | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
11219L | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,332 | 2,024 | SEPTEMBER |
End of preview. Expand
in Dataset Viewer.
README.md exists but content is empty.
Use the Edit dataset card button to edit it.
- Downloads last month
- 88